EVE group:Everolimus 10mg PO QD

2 trials

Sponsors

Department of neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Renji Hospital, Shanghai Jiao Tong University School of Medicine

Conditions

Malignant Gliomarefractory recurrent atypical and malignant meningiomas

Phase 1

Clinical study of PD-L1 inhibitor combined with everolimus in the treatment of refractory recurrent atypical and malignant meningiomas

Active, not recruitingChiCTR2000036064

Department of neurosurgery, Beijing Tiantan Hospital, Capital Medical Universityrefractory recurrent atypical and malignant meningiomas

Start: 2020-09-01Updated: 2020-08-31

Unknown Phase

Clinical study of PD-1 inhibitor with everolimus for relapsed and refractory brain tumors

RecruitingChiCTR-OON-16008330

Renji Hospital, Shanghai Jiao Tong University School of MedicineMalignant Glioma

Start: 2015-08-01Updated: 2017-04-18

Related Papers

Abstract CT161: Clinical study of PD-1 inhibitor with mTOR inhibitor for relapsed and refractory brain tumors

Cancer Research2018-07-011 citations